Skip to main content
Clinical Trials/NCT05060172
NCT05060172
Completed
Not Applicable

A Cross-sectional, Interventional, Single-arm Clinical Study for Validating the Equivalence of Bloomlife MFM-Pro to Clinical Standard-of-care for Antepartum Fetal Monitoring

Bloom Technologies1 site in 1 country96 target enrollmentJune 25, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fetal Monitoring
Sponsor
Bloom Technologies
Enrollment
96
Locations
1
Primary Endpoint
Extent of agreement between Bloomlife MFM-Pro and CTG in maternal heart rate
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Bloomlife has developed a wearable system (Bloomlife MFM-Pro) that can allow fetal monitoring to be conveniently performed in healthcare settings under supervision of a healthcare professional.

Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.

The purpose of this study is to validate that the Bloomlife MFM-Pro is equivalent to clinical standard-of-care for routine non-stress test (NST) performed at the hospital.

Registry
clinicaltrials.gov
Start Date
June 25, 2021
End Date
November 25, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
Bloom Technologies
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Pregnant woman ≥ 18 years old
  • Gestational age ≥ 32 weeks and 0 days
  • Singleton pregnancy
  • Ability to read and understand Dutch or English
  • Willingness to participate in the study

Exclusion Criteria

  • Implanted pacemaker or any other implanted electrical device
  • Plurality higher than 1
  • History of allergies to skin adhesives
  • Contraindication to the use of the CTG

Outcomes

Primary Outcomes

Extent of agreement between Bloomlife MFM-Pro and CTG in maternal heart rate

Time Frame: 1 hour

Bland-Altman analysis, based on a 95% limits of agreement

Extent of agreement between Bloomlife MFM-Pro and CTG in fetal heart rate

Time Frame: 1 hour

Bland-Altman analysis, based on a 95% limits of agreement

Study Sites (1)

Loading locations...

Similar Trials